Skip to search formSkip to main contentSkip to account menu

PF-4989216

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ThiophenesTriazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
In early 2017, a representative from Pfizer contacted the CCR editorial office to request a retraction of the above-mentioned… 
2014
2014
Cancer Therapy : Preclinical Targeting Small Cell Lung Cancer Harboring PIK 3 CA Mutation with a Selective Oral PI 3 K Inhibitor PF-4989216
Purpose:Constitutive activation of phosphoinositide 3-kinase (PI3K) occurs frequently inmany human tumors via either gene… 
2013
2013
Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Purpose: Constitutive activation of phosphoinositide 3-kinase (PI3K) occurs frequently in many human tumors via either gene… 
2013
2013
Abstract 3257: Targeting small cell lung cancer harboringPIK3CAmutation with a selective oral PI3K inhibitor, PF-4989216.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)